Initial Dosing of Valproic Acid for Bipolar 1 Mania

Dosing Strategy

For acute mania in bipolar I disorder, valproic acid is a first-line treatment option along with lithium and atypical antipsychotics, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 2
For more conservative dosing, some clinicians start with 125 mg twice daily and titrate upward, according to the American Academy of Family Physicians 3

After initial dosing, titrate to therapeutic blood levels (40-90 μg/mL), as recommended by the American Academy of Family Physicians 3
A 6-8 week trial at adequate doses is recommended before adding or substituting other mood stabilizers, according to the American Academy of Child and Adolescent Psychiatry 4

Before initiating valproate therapy, baseline liver function tests, complete blood cell count, and pregnancy test in females of reproductive age are recommended by the American Academy of Child and Adolescent Psychiatry 4
During treatment, monitor serum drug levels periodically (every 3-6 months), as recommended by the American Academy of Child and Adolescent Psychiatry 4
Monitor hepatic and hematological indices regularly, and be aware of concerns regarding valproate and development of polycystic ovary disease in females, according to the American Academy of Child and Adolescent Psychiatry 4

Valproate is FDA-approved for acute mania in adults, as noted by the American Academy of Child and Adolescent Psychiatry 1, 5
Generally, valproate is better tolerated than other mood stabilizers, according to the American Academy of Family Physicians 3
Do not use valproate as monotherapy in patients with bipolar depression; it should be combined with an antidepressant, as recommended by the PLoS Medicine 6
Be cautious about using valproate in women of childbearing potential due to teratogenic risks, according to the American Academy of Child and Adolescent Psychiatry 4
Avoid unnecessary polypharmacy; start with monotherapy before considering combinations, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 5
Do not rely solely on periodic lab monitoring; educate patients about symptoms of potential adverse effects, according to the American Academy of Child and Adolescent Psychiatry 4